|
 
- 积分
- 3053
- 威望
- 3053
- 包包
- 5595
|
Glance at last issue:& M- A [1 T2 c% d/ @3 f0 ~. o
" ]4 Q* J+ Q& j. h* R& Q: g“Our stem cell research is application-driven. If you want to make stem cell therapies feasible, affordable and reproducible, we know you have to overcome a few hurdles. Part of the problem in our health care industry is that you have a treatment, but it often costs too much. In the case of stem cell treatments, isolating stem cells is very expensive. The cells we have engineered grow continuously in the laboratory, which brings down the price of treatments.”--Dr. Techung Lee at the University at Buffalo.
5 F! H+ ^( B# z- ^; o7 v0 F+ ^& i# F6 @; _0 s
“Bioinformatics is a research area that is becoming increasingly important for all fields in biology. The vast amount of data that is now available can only be effectively utilized with a solid understanding of its interpretation. Our studies in Australia will be crucial for keeping the lab at the frontline of stem cell research.”--Dr. Nagy, a Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital.
0 x9 M) O/ M' a* {2 l8 p8 C
/ c; v. A2 G& R"It's not as if cancer cells invent this program. They reach back into their early origins in the embryo, turning on genes and behavioral programs that in adult cells are usually shut down."--Robert Weinberg, a cancer researcher at Massachusetts Institute of Technology.
}" @% A0 G, u& G) A& x D: |
"The clinical implications of this concept are huge. If we're not able to design therapies to target this self-renewing population of chemotherapy-resistant cells, the patients will continue to have a tendency to relapse."--Acting assistant professor of oncology Ash Alizadeh, MD. at Stanford University School of Medicine.
5 p0 W2 J* ^1 T4 e" S4 k9 @' I# A7 L/ W) P# d) j7 Y- }0 q" B$ c. b
"The stronger the leukemia stem cell signal, the worse the patients did. Their lives were shorter, they relapsed sooner and they were less able to respond to therapy..."We'd like to know whether a group of patients with a high leukemic stem cell burden would respond well to certain types of therapy, and which should be avoided. For example, bone marrow transplant can sometimes be an effective way to treat AML.But transplant itself carries significant risks for the patient. If it is not likely to help someone with high levels of expression of these genes, then we can try other approaches."--Gentles, who is a member of the Stanford Center for Cancer Systems Biology.
% g# f( X# Z( O: ?6 F3 K, Q1 O, x" l5 |. {0 e; o: x1 Q2 }. @# X3 |( u9 y
"AMR-001 is the first stem cell therapy to demonstrate neoangiogenesis (formation of new blood vessels) in a threshold dose, in heart muscle damaged from a severe heart attack. We look forward to further evaluating AMR-001 in a larger Phase II trial where we look toward duplicating the neoangiogenisis achieved in the Phase I trial and also to achieve a significant reduction in downstream adverse events typically resulting from AMI."--Andrew Pecora, M.D., Amorcyte Founder and Chief Science Officer./ H' _ y# t m2 s9 L( d
8 _# p: k0 d" v4 r$ k& H9 E
% I$ J( a7 ~& v% b) l) L: rThis issue:5 D. v: Z% D0 r
|
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 20
包包 + 30
查看全部评分
|
发表于 2010-12-26 22:17
